Massachusetts Financial Services CO Eagle Pharmaceuticals, Inc. Transaction History

Massachusetts Financial Services CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$4.63 - $15.21 $4,444 - $14,601	-960 Reduced 3.06%	30,396 $158,000
Q3 2023 Nov 08, 2023	SELL	$15.21 - $22.88 $18,297 - $27,524	-1,203 Reduced 3.69%	31,356 $494,000
Q2 2023 Aug 09, 2023	SELL	$17.74 - $31.87 $13,606 - $24,444	-767 Reduced 2.3%	32,559 $632,000
Q1 2023 May 10, 2023	BUY	$25.06 - $34.09 $350,965 - $477,430	14,005 Added 72.49%	33,326 $945,000
Q4 2022 Feb 13, 2023	BUY	$24.98 - $39.77 $10,166 - $16,186	407 Added 2.15%	19,321 $564,000
Q3 2022 Nov 09, 2022	BUY	$26.42 - $47.12 $133,817 - $238,662	5,065 Added 36.57%	18,914 $500,000
Q2 2022 Aug 09, 2022	BUY	$41.26 - $51.35 $571,409 - $711,146	13,849 New	13,849 $615,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.